Brian Taylor Slingsby

CIK: 0001963901

Transaction Breakdown

Open Market Buys (P)1 (9.1%)

High conviction signal

Open Market Sales (S)2 (18.2%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (18.2%)

Compensation grants

Other (G, F, J, C, D, …)6 (54.5%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

MLYS

Mineralys Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (11 total)

MLYS
Mineralys Therapeutics, Inc.
Sep 22, 2026
Sale(S)
Indirect
104.3K shares at avg. $28.81$3.0M
MLYS
Mineralys Therapeutics, Inc.
Feb 19, 2026
Award(A)
Direct
6.2K shares-
MLYS
Mineralys Therapeutics, Inc.
Feb 19, 2026
Other(J)
Direct
6.2K shares-
MLYS
Mineralys Therapeutics, Inc.
Feb 19, 2026
Other(J)
Indirect
6.2K shares-
MLYS
Mineralys Therapeutics, Inc.
Nov 20, 2025
Sale(S)
Indirect
1M shares at avg. $43.35$43.4M
MLYS
Mineralys Therapeutics, Inc.
Mar 13, 2025
Purchase(P)
Indirect
259.3K shares at avg. $13.50$3.5M
MLYS
Mineralys Therapeutics, Inc.
Feb 13, 2025
Award(A)
Stock Option
Direct
32.9K shares-
MLYS
Mineralys Therapeutics, Inc.
Feb 13, 2025
Other(J)
Stock Option
Direct
32.9K shares-
MLYS
Mineralys Therapeutics, Inc.
Feb 13, 2025
Other(J)
Stock Option
Indirect
32.9K shares-
MLYS
Mineralys Therapeutics, Inc.
May 22, 2024
Other(J)
Stock Option
Direct
22K shares-
MLYS
Mineralys Therapeutics, Inc.
May 22, 2024
Other(J)
Stock Option
Indirect
22K shares-

		Type	Shares	Price		Ownership
Sep 22, 2026	MLYS Mineralys Therapeutics, Inc.	Sale(S)	104,320	$28.81	$3,005,303	Indirect
Feb 19, 2026	MLYS Mineralys Therapeutics, Inc.	Award(A)	6,200	-	$0	Direct
Feb 19, 2026	MLYS Mineralys Therapeutics, Inc.	Other(J)	6,200	-	$0	Direct
Feb 19, 2026	MLYS Mineralys Therapeutics, Inc.	Other(J)	6,200	-	$0	Indirect
Nov 20, 2025	MLYS Mineralys Therapeutics, Inc.	Sale(S)	1,000,000	$43.35	$43,350,000	Indirect
Mar 13, 2025	MLYS Mineralys Therapeutics, Inc.	Purchase(P)	259,259	$13.50	$3,499,997	Indirect
Feb 13, 2025	MLYS Mineralys Therapeutics, Inc.	Award(A) Stock Option	32,900	-	-	Direct
Feb 13, 2025	MLYS Mineralys Therapeutics, Inc.	Other(J) Stock Option	32,900	-	-	Direct
Feb 13, 2025	MLYS Mineralys Therapeutics, Inc.	Other(J) Stock Option	32,900	-	-	Indirect
May 22, 2024	MLYS Mineralys Therapeutics, Inc.	Other(J) Stock Option	22,000	-	-	Direct
May 22, 2024	MLYS Mineralys Therapeutics, Inc.	Other(J) Stock Option	22,000	-	-	Indirect

1-11 of 11 transactions

About Slingsby Brian Taylor

Slingsby Brian Taylor (SEC CIK 0001963901) files insider reports with the SEC as Director of Mineralys Therapeutics, Inc. (MLYS).

Signal8 holds 6 ownership filings by Slingsby Brian Taylor, all Form 4s, filed between Jan 7, 2025 and Sep 24, 2026. Those filings report 11 transactions, from May 22, 2024 to Sep 22, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Slingsby Brian Taylor's filings is in SEATTLE, WA.

Recent filings by Slingsby Brian Taylor

Sep 22, 2026: Open-market sale of MLYS shares (Form 4, code S).
Feb 19, 2026: Grant or award of MLYS shares (Form 4, code A).
Feb 19, 2026: Other transactions of MLYS shares (2 lines, Form 4, code J).
Nov 20, 2025: Open-market sale of MLYS shares (Form 4, code S).
Mar 13, 2025: Open-market purchase of MLYS shares (Form 4, code P).

Other insiders filing for Mineralys Therapeutics, Inc. (MLYS)

Peterson Kristine, Director
COATS LONNEL, Director
Congleton Jon, Chief Executive Officer
Warren Eric, Chief Commercial Officer
Karydas Daphne, Director
Ferguson James J. III, Chief Medical Officer

How to read Form 4 transaction codes